Dexamethasone attenuates bleomycin-induced lung fibrosis in mice through TGF-β, Smad3 and JAK-STAT pathway

Keyun Shi1, Jianzhong Jiang1, Tieliang Ma2, Jing Xie1, Lirong Duan3, Ruhua Chen4, Ping Song5, Zhixin Yu5, Chao Liu5, Qin Zhu5, Jinxu Zheng5

1Department of Geriatrics, The Affiliated Yixing Hospital of Jiangsu University, Yixing, Jiangsu, China; 2Central Laboratory, The Affiliated Yixing Hospital of Jiangsu University, Yixing, Jiangsu, China; 3School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang, Jiangsu, China; 4Department of Respiratory, The Affiliated Yixing Hospital of Jiangsu University, Yixing, Jiangsu, China; 5Department of Respiratory, The Affiliated Jiangbin Hospital of Jiangsu University, Zhenjiang, Jiangsu, China

Received July 22, 2014; Accepted August 26, 2014; Epub September 15, 2014; Published September 30, 2014

Abstract: In order to find the possible mechanism of Dexamethasone (Dex) during curing fibrosis, the bleomycin (BLM)-induced mice model was used. After fibrosis were induced by BLM, histopathological evaluation and RT-PCR were employed to detect the expression of TGF-β1, Smad3 and STAT1. It was found that BLM promoted the development of inflammation, leading to severe pulmonary fibrosis with the increasing of TGF-β1, Smad3 and STAT1. After Dex treatment, the expression of TGF-β1, Smad3 and STAT1 showed a little higher with alleviation of the fibrosis. Thus it is concluded that there is a possible pathway of mouse pulmonary fibrosis model through TGF-β, Smad3 and JAK-STAT pathway.

Keywords: Bleomycin, dexamethasone, idiopathic pulmonary fibrosis, Smad3, JAK-STAT

Introduction

It is currently believed that idiopathic pulmonary fibrosis is an epithelial-fibroblastic disease. Risk factors associated with pulmonary fibrosis include smoking, environmental exposure, gastroesophageal reflux disease, genetic factors, diabetes mellitus, infectious agents, and commonly prescribed drugs, such as BLM [1]. Current therapeutic strategies are primarily aimed at controlling the inflammatory processes, often through the oral administration of glucocorticosteroids, which have been the first line of therapy for pulmonary fibrosis since the 1950s [2].

BLM plays an important role in the treatment of lymphoma, squamous cell carcinomas, germ cell tumors and malignant pleural effusion, where it is injected intrapleurally [3]. However, it is believed that BLM acts by causing single and double-strand DNA breaks in tumor cells. Pulmonary fibrosis develops in ~ 1% of patients receiving BLM [4]. BLM as an agent to induce experimental lung fibrosis was described in a lot of animals [5, 6]. BLM induced animal models of experimental lung fibrosis often be employed to study the IPF. BLM causes inflammatory and fibrotic reactions within a short period of time, even more so after intratracheal instillation.

One study examining possibly safer therapies for pulmonary fibrosis revealed that low doses of DEX delivered constantly by autologous erythrocytes slowed the progression of lung disease [7].

In the early injury or inflammation, TGF-β promotes the development of inflammation, and increases activity at sites of inflammation, and induces the proliferation of the fibroblasts, leading to severe pulmonary fibrosis. The fulfilling of TGF-β function depends on the signal transduction and regulation of Smads proteins. Smad2/3 is mediated by TGF-β-induced liver fibrosis key elements [8].
In recent years, studies have shown the abnormal activation of STAT1 in BLM-induced mouse pulmonary fibrosis model [9], and STAT1 was involved in alveolitis and pulmonary fibrosis in the alveolar macrophages (AM). We also found that there is a pathway of pathogenesis in BLM-

Figure 1. Histological section of lung fields (A-E). The lung sections were stained with HE (A: The control group, B: The bleomycin (BLM) model group 3 d, C: The BLM model group 28 d, D: The BLM model plus dexamethasone (DEX) group 3 d, E: The BLM model plus Dex group 28 d). The results of the control group were normal (A); the pulmonary tissues in the BLM group had apparent fibrotic changes (B, C); and it shows a mild fibrosis in the alveoli and interstitium by Dex treatment (D, E). Bar: 100 μm.
Dexamethasone attenuates bleomycin-induced lung fibrosis

Table 1. TGF-β1 immunohistochemical staining by comparison of the average IOD values

<table>
<thead>
<tr>
<th>Group</th>
<th>7 d</th>
<th>14 d</th>
<th>28 d</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>13.34±1.12</td>
<td>13.23±0.99</td>
<td>13.16±0.87</td>
</tr>
<tr>
<td>BLM</td>
<td>32.93±1.77**</td>
<td>29.09±1.56**</td>
<td>25.79±1.55*</td>
</tr>
<tr>
<td>Dex</td>
<td>26.37±2.38**†</td>
<td>23.23±2.14**</td>
<td>18.22±1.36**†</td>
</tr>
</tbody>
</table>

Data are mean ± SEM, n=15, *p<0.05, **p<0.01, †p<0.05.

BLM-induced mouse model that involves the TGF-β1, IL-31 and JAKs/STATs pathway [10]. Finally, DEX affects the development of pulmonary fibrosis through TGF-β, Smad2/3, JAK-STAT. A BLM-induced mouse pulmonary fibrosis model was used to test the possible pathway of the DEX.

Materials and methods

Chemicals and reagents

BLM A5 hydrochloride and DEX were purchased from Zhejiang Haizheng (Hangzhou, China). The RT-PCR kit was obtained from Promega (WI, USA) and the PCR primers were synthesized by Bioasia Biologic Technology (Shanghai, China). The mouse antibodies of TGF-β1, Smad3 were purchased from Boster Bio-Engineering (Wuhan, China). All other chemicals were of the highest commercial grade available.

Animals

The studies described in this report were approved by the Animal Review Committee of Jiangsu University. CD-1 mice (Shanghai Laboratory Animal Center, Chinese Academy of Sciences, Shanghai, China) were maintained in a controlled environment and provided with water and standard rodent food.

Mouse model

60 mice were randomly divided into the following 3 groups (n=20 each): saline-water; BLM-water; BLM plus DEX. Mice in the saline group were injected intratracheally with 2 ml/kg saline; the others were injected intratracheally with BLM (5 mg/kg, 2 ml/kg in saline). Twenty-four hours after BLM treatment, mice were given by gavage 0.45 mg/kg/d DEX. The day of intratracheal injection with BLM or saline was designated day 0.

Histopathological evaluation

Mouse lung tissues were processed for routine paraffin embedding, and serial sections (5 μm) were stained with hematoxylin and eosin. The extent of alveolitis and fibrosis was blindly assessed using the previously described semi-quantitative criteria [11]. Tissues from all the mice were embedded in paraffin. Five μm-thick paraffin sections were collected by microscope slides. The sections were blocked and incubated with mouse anti-TGF-β1 and SMAD3 antibodies (Wuhan, China) and a biotinylated and streptomycin-labeled goat anti-mouse antibody (Wuhan, China). Cyclin D1 expression was detected by the reaction of peroxidase with 3, 3'-diaminobenzidine tetrahydrochloride (DAB).

RT-PCR analysis for cellular factors

Total RNA was extracted from 100-mg frozen lung tissue using the TRI Reagent (Sigma, MO, USA), and 2 μg of total RNA were reverse transcribed into cDNA at 42°C for 1 h with Moloney murine leukemia virus reverse transcriptase (Promega, WI, USA). The following primers were used for PCR: STAT1 (5'-ttgtgttgaatcccgaacct-3'; 5'-tcgaaccactgtgacatcct-3'), Actin (5'-gtccctcaccctccaaaaag-3'; 5'-gctgcctcaacacctcaaccc-3'). Amplifications were for 40 cycles of 60 s at 95°C, 45 s at 60°C, and 75 s at 72°C, and the PCR products were visualized on a 2% agarose gel using a Molecular Analyst Densitometer (Bio-Rad, Hercules, CA).

Statistical methods

Results are given as means ± SD. The differences were assessed by Student’s t-test, one-way or two-way ANOVA using Bonferroni post-tests as appropriate. A P value of <0.05 was considered to indicate a significant difference.

Results

The mouse model of pulmonary fibrosis and effect of DEX treatment

BLM administration resulted in the development of extensive fibrosis areas in the lung on day 28 after treatment. Dex administration attenuated pulmonary fibrosis. Histopathology showed that mice in the control group had a normal structure (Figure 1A). On day 3 post treatment, BLM treated mice and Dex treated mice showed mild fibrosis in the alveoli and interstitium (Figure 1B, 1D). On day 28, BLM treated mice showed marked histopathological changes, such as large fibrous areas and col-
Dexamethasone attenuates bleomycin-induced lung fibrosis

Figure 2. Immunohistological staining for Smad3 in the lung fields (A: The control group, B: The BLM model group, C: The BLM plus Dex group). Fewer positively stained cells were seen in the BLM plus Dex group (C) than in the BLM group (B); Smad3 expression was significantly weak in the control group (A). Bar: 100 μm.

Figure 3. RT-PCR for STAT1 mRNA in different groups. STAT1 mRNA bands were measured by densitometric analysis and normalized with GAPDH. For each group n=15. Data are expressed as the mean ± SEM. *P<0.05. **P<0.01.

lapsed alveolar spaces (Figure 1C). However, Dex treated mice only showed mild fibrosis at day 28 (Figure 1E).

The expression of TGF-β1 detected by immunohistochemical staining

The sections at different times were stained by anti TGF-β1 antibodies. This marker expressed weakly in control lung tissues. At 7 and 14 days after BLM treatment, the signal of TGF-β1 was significantly stronger than that of the control group. At 28 days after treatment, the TGF-β1 signal became a little weaker. At 7 and 14 days of BLM plus Dex group, the signal of TGF-β1 was also stronger than that of the control group.

However, at 28 days, the TGF-β1 signal became weaker and was a little stronger than the level of control group. All the results were given by comparison of the average IOD value (Table 1).

The expression of Smad3 of mice lung tissue

Immunohistochemical staining was performed to detect the expression of Smad3 in the alveolar macrophages and alveolar epithelial cells. We found the expression of Smad3 increased significantly after treatment from 3 d to 28 d (Figure 2B). However, after treated with Dex, the expression level became weaker (Figure 2C).

The expression of STAT1 mRNA of mice lung tissues

The lung tissues of mice after BLM treatment at different days were collected and extracted mRNA. Then, RT-PCR technology was employed to get the expression of STAT1 gene. We found that the STAT1 gene was upregulated in mice lung after treated by BLM, even at 7 days after treatment (Figure 3). STAT1 gene was detected at a more high level in the model group. It expressed at the most high level at 14 d and becomes lower at 21 d and 28 d.
Discussion

In the present study, DEX was used in BLM-induced fibrosis mouse model, and as previous studies, DEX attenuated pulmonary fibrosis induced by BLM. The molecules TGF-β1, Smad3 and JAK-STAT increased after BLM treatment and showed decreasing trend. Because of the expressions of these molecules are in a similar mode whether in the BLM-induced model or BLM plus Dex group. Therefore, we speculate that they may constitute a possible pathway of mouse pulmonary fibrosis.

In a previous clinical report, short-term treatment with the corticosteroid DEX started 12-48 h after birth in infants with neonatal respiratory distress syndrome, increased survival without causing bronchopulmonary dysplasia [12]. This suggests that DEX treatment after injury is able to prevent lung fibrosis. Furthermore, one study revealed that low doses of DEX delivered constantly by autologous erythrocytes slowed the progression of lung disease such as pulmonary fibrosis. And in our result, we also saw the attenuating function of DEX.

TGF-β1 is a key molecule in the development and progression of pulmonary fibrosis. It promotes the transcription of collagen type I and fibronectin in fibroblasts through an intricate signaling cascade. In this study, TGF-β1 expression became significantly higher after BLM treatment and was a little lower if DEX was added.

A family of transcription factors, called Smad proteins [13, 14] is intracellular signaling pathway downstream to the TGF-β1 receptors. Activation of the type I receptor results in phosphorylation of the pathway-restricted Smad2 and Smad3, which then form a heteromeric complex with Smad4 [13, 14]. We found the expression of Smad3 is similar with TGF-β1. Therefore, we suspect that Smad3 is a downstream of TGF-β1 in the BLM-induced mice model.

Another study found that STAT-1 was abnormally activated in alveolar macrophages (AMs) of rats with BLM-induced interstitial pulmonary fibrosis (IPF) [9]. The abnormal STAT-1 activation may play a role in the pathogenesis of acute alveolitis and pulmonary fibrosis. Other previous studies found JAKs/STATs pathway is important in lung disease.

The data from this study show that it is a possible pathway of pulmonary fibrosis. And the rescue function of DEX further confirmed this pathway. It begins at TGF-β1. TGF-β1 induced Smad2 phosphorylation finally stimulates the JAK-STAT.

Acknowledgements

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. This work was funded by Jiangsu University Clinical Science and Technology Development Fund (JLY2012063), and Natural Science Foundation of Shanghai (10ZR1422600).

Address correspondence to: Jinxu Zheng, Department of Respiratory, Jiangbin Hospital of Jiangsu University, Zhenjiang 212000, Jiangsu, CN, China. E-mail: 2593147703@qq.com

References

Dexamethasone attenuates bleomycin-induced lung fibrosis